SCHEMBL1233658

SCHEMBL1233658

COc1ccc(NC(=O)c2ccc(Cl)nc2)c(N)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 1/20 0.55
KCNQ3 O43525 2/20 0.54
KCNQ2 O43526 2/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
F10 P00742 1/20 0.52
HDAC1 Q13547 4/20 0.52
HDAC3 O15379 3/20 0.52
HDAC2 Q92769 3/20 0.52
HDAC4 P56524 2/20 0.52
HDAC7 Q8WUI4 2/20 0.52
HDAC10 Q969S8 2/20 0.52
HDAC11 Q96DB2 2/20 0.52
HDAC8 Q9BY41 2/20 0.52
HDAC6 Q9UBN7 2/20 0.52
HDAC9 Q9UKV0 2/20 0.52
HDAC5 Q9UQL6 2/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
RAB9A P51151 4/20 0.52
MAPK1 P28482 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303029 0.86 KMT2A (0.59) P4HTMKCNQ3KCNQ2MEN1KMT2A
SCHEMBL4061498 0.86 P4HTM (0.72) P4HTMKCNQ3KCNQ2MEN1KMT2A
SCHEMBL3199765 0.86 P4HTM (0.56) P4HTMKCNQ3KCNQ2MEN1KMT2A
SCHEMBL1235341 0.84 RAB9A (0.63) KCNQ3KCNQ2MEN1KMT2AHDAC1
SCHEMBL1235368 0.83 HDAC1 (0.60) KCNQ3KCNQ2MEN1KMT2AF10
SCHEMBL6705958 0.81 MAPT (0.68) MEN1KMT2ASMN1; SMN2RAB9AMAPK1
SCHEMBL1233691 0.81 HDAC1 (0.68) KCNQ3KCNQ2HDAC1HDAC3HDAC2
SCHEMBL1235248 0.81 HDAC1 (0.66) P4HTMF10HDAC1HDAC3HDAC2
SCHEMBL2302302 0.79 RAB9A (0.72) P4HTMKCNQ3KCNQ2MEN1KMT2A
SCHEMBL27835137 0.79 HDAC1 (0.52) MEN1KMT2AF10HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102020638-B 2-indolinone derivative with protein kinase inhibition activity and histone deacetylase inhibition activity and preparation method and application thereof SHENZHEN CHIPSCREEN BIOSCIENCES LTD 2013-05-08 CN disclosed
CN-102020607-B 6-aminoniacinamide derivatives with histone deacetylase inhibiting activity, preparation method and application thereof SHENZHEN CHIPSCREEN BIOSCIENCES LTD 2013-01-23 CN disclosed
US-8158656-B2 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) 2012-04-17 US disclosed
US-8158656-B2 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) 2012-04-17 US disclosed
US-8158656-B2 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) 2012-04-17 US disclosed
EP-2285376-A1 6-AMINONICOTINAMIDE DERIVATIVES AS POTENT AND SELECTIVE HISTONE DEACETYLASE INHIBITORS Chipscreen Biosciences Ltd. (CN) 2011-02-23 EP disclosed
US-20090298886-A1 2-INDOLINONE DERIVATIVES AS MULTI-TARGET PROTEIN KINASE INHIBITORS AND HISTONE DEACETYLASE INHIBITORS CHIPSCREEN BIOSCIENCES, LTD. (CN) 2009-12-03 US disclosed
US-20090298886-A1 2-INDOLINONE DERIVATIVES AS MULTI-TARGET PROTEIN KINASE INHIBITORS AND HISTONE DEACETYLASE INHIBITORS CHIPSCREEN BIOSCIENCES, LTD. (CN) 2009-12-03 US disclosed
US-20090298886-A1 2-INDOLINONE DERIVATIVES AS MULTI-TARGET PROTEIN KINASE INHIBITORS AND HISTONE DEACETYLASE INHIBITORS CHIPSCREEN BIOSCIENCES, LTD. (CN) 2009-12-03 US disclosed
WO-2009140164-A1 6-AMINONICOTINAMIDE DERIVATIVES AS POTENT AND SELECTIVE HISTONE DEACETYLASE INHIBITORS CHIPSCREEN BIOSCIENCES LTD. (CN) 2009-11-19 WO disclosed
WO-2009140164-A1 6-AMINONICOTINAMIDE DERIVATIVES AS POTENT AND SELECTIVE HISTONE DEACETYLASE INHIBITORS CHIPSCREEN BIOSCIENCES LTD. (CN) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298886-A1 2-INDOLINONE DERIVATIVES AS MULTI-TARGET PROTEIN KINASE INHIBITORS AND HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC2, HDAC3 P4HTM 3295/4885KCNQ3 3519/4885KCNQ2 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.